NCT06689085Phase 3Recruiting

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Study sponsor: Halozyme Therapeutics

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2028-03Estimated
Enrollment · participants100Estimated
Source updated2026-02-18Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Primary completion date changed

− Before

Oct 2027

+ After

Mar 2028

Check registry source